Last reviewed · How we verify

EMLA cream 5%

HaEmek Medical Center, Israel · FDA-approved active Small molecule Quality 5/100

EMLA cream 5% is a Small molecule drug developed by HaEmek Medical Center, Israel. It is currently FDA-approved. Also known as: no other names, Standard EMLA 5% patch.

EMLA cream 5%, marketed by HaEmek Medical Center, is a topical anesthetic with a well-established presence in the market. The drug's key strength lies in its composition patent, which is set to expire in 2028, providing a period of exclusive market protection. The primary risk is the potential increase in competition following the patent expiry, which could impact revenue.

At a glance

Generic nameEMLA cream 5%
Also known asno other names, Standard EMLA 5% patch
SponsorHaEmek Medical Center, Israel
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about EMLA cream 5%

What is EMLA cream 5%?

EMLA cream 5% is a Small molecule drug developed by HaEmek Medical Center, Israel.

Who makes EMLA cream 5%?

EMLA cream 5% is developed and marketed by HaEmek Medical Center, Israel (see full HaEmek Medical Center, Israel pipeline at /company/haemek-medical-center-israel).

Is EMLA cream 5% also known as anything else?

EMLA cream 5% is also known as no other names, Standard EMLA 5% patch.

What development phase is EMLA cream 5% in?

EMLA cream 5% is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing